Literature DB >> 8894620

Thromboxane A2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells.

T Ishizuka1, K Suzuki, M Kawakami, T Hidaka, Y Matsuki, H Nakamura.   

Abstract

Inhibition of the thromboxane A2-synthesizing enzyme (DP-1904: [+/-]-6-[1-imidazolylmethyl]-5,6,7,8-tetrahydronaphthalene-2-carbo xylic acid hydrochloride hemihydrate) reportedly suppresses intercellular adhesion molecule-1 (ICAM-1) expression on the surface of stimulated vascular endothelial cells (Ishizuka et al., 1994, Eur. J. Pharmacol 262, 113). In the present study, thromboxane A2 receptor antagonists suppressed the expression of ICAM-1 on the surface of human vascular endothelial cells that were stimulated by tumor necrosis factor alpha (TNF alpha), platelet activating factor (PAF), or U46619 (9,11-dideoxy-9 alpha, 11 alpha-epoxymethanoprostaglandin F2 alpha). Augmentation of ICAM-1 expression on human vascular endothelial cells stimulated by U46619 was suppressed by protein kinase C inhibitors. Thromboxane A2 receptor antagonist suppressed U46619 stimulation of protein kinase C activity of a cell membrane fraction. These results indicate that in human vascular endothelial cells, thromboxane A2, the production and secretion of which is stimulated by TNF alpha or PAF, binds to the thromboxane A2 receptors on cell membranes and augments ICAM-1 expression on the cell surfaces mainly through protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894620     DOI: 10.1016/0014-2999(96)00478-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player.

Authors:  Michael Bode; Nigel Mackman
Journal:  Vascul Pharmacol       Date:  2014-05-21       Impact factor: 5.773

Review 2.  Molecular insights and therapeutic targets for diabetic endothelial dysfunction.

Authors:  Jian Xu; Ming-Hui Zou
Journal:  Circulation       Date:  2009-09-29       Impact factor: 29.690

3.  Maternal levels of prostacyclin, thromboxane, ICAM, and VCAM in normal and preeclamptic pregnancies.

Authors:  David F Lewis; Bernard J Canzoneri; Yang Gu; Shuang Zhao; Yuping Wang
Journal:  Am J Reprod Immunol       Date:  2010-12       Impact factor: 3.886

Review 4.  Platelets in patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

Review 5.  TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis.

Authors:  Michel Félétou; Richard A Cohen; Paul M Vanhoutte; Tony J Verbeuren
Journal:  Adv Pharmacol       Date:  2010

6.  Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein-1 (MCP-1) expression by stimulated vascular endothelial cells.

Authors:  T Ishizuka; S Sawada; K Sugama; A Kurita
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

7.  Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells.

Authors:  T Ishizuka; M Kawakami; T Hidaka; Y Matsuki; M Takamizawa; K Suzuki; A Kurita; H Nakamura
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

8.  COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity.

Authors:  Dingxin Pan; Kathleen M Buchheit; Sachin K Samuchiwal; Tao Liu; Haley Cirka; Hannah Raff; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-07-12       Impact factor: 10.793

9.  Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.

Authors:  Tao Liu; Tanya M Laidlaw; Howard R Katz; Joshua A Boyce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-01       Impact factor: 11.205

10.  Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease.

Authors:  Nan Wang; Kimberly C Vendrov; Brian P Simmons; Robert N Schuck; George A Stouffer; Craig R Lee
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-11-16       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.